Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock has already tripled this year, on renewed hopes of success for an experimental lupus treatment. Despite this year's big run-up, this clinical-stage biotech stock could still be a gold mine for growth investors.
Aurinia shares probably would have jumped much higher if a safety scare and mixed data for the company's lead candidate weren't weighing on investors' minds. Here's why that pessimism might be overblown.
Source: Fool.com
Novartis AG ADR Stock
€102.00
0.000%
Our community is currently high on Novartis AG ADR with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 112 € shows a slightly positive potential of 9.8% compared to the current price of 102.0 € for Novartis AG ADR.